Brief: OSE Immunotherapeutics: OSE-230 Triggers Resolution Of Chronic Inflammation

Ose Immunotherapeutics SA

30/10/2020 06:36

Oct 30 (Reuters) - OSE IMMUNOTHERAPEUTICS SA  OSE.PA :
    * OSE IMMUNOTHERAPEUTICS PRESENTS OSE-230 AS A NOVEL AGONIST
MONOCLONAL ANTIBODY THERAPY TRIGGERING RESOLUTION OF CHRONIC
INFLAMMATION
    * FIRST PRESENTATION OF NEW DATA CHARACTERIZING
THEANTI-CHEMR23
ANTIBODY WAS AT FOCIS VIRTUAL ANNUAL MEETING HELD OCTOBER 28-31,
2020
    * OSE-230 INDUCES INFLAMMATION RESOLUTION ACCELERATION IN
VIVO IN
ACUTE INFLAMMATORY PRECLINICAL MODELS
    * OSE-230 TRIGGERS EFFICIENT RESOLUTION OF INFLAMMATION IN
CHRONIC
COLITIS MODELS WHICH SPONTANEOUSLY DO NOT RESOLVE
    * PRECLINICAL STUDIES ALSO DEMONSTRATED RESOLUTION OF
INFLAMMATION
IN TYPE 1 DIABETES AND MULTIPLE SCLEROSIS MODELS

Source text for Eikon:  ID:nBwwRvk3a 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))